4C62

Inhibitors of Jak2 Kinase domain


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.75 Å
  • R-Value Free: 0.246 
  • R-Value Work: 0.196 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

Discovery of 1-Methyl-1H-Imidazole Derivatives as Potent Jak2 Inhibitors.

Su, Q.Ioannidis, S.Chuaqui, C.Almeida, L.Alimzhanov, M.Bebernitz, G.Bell, K.Block, M.Howard, T.Huang, S.Huszar, D.Read, J.A.Rivard Costa, C.Shi, J.Su, M.Ye, M.Zinda, M.

(2014) J.Med.Chem. 57: 144

  • DOI: 10.1021/jm401546n
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Structure based design, synthesis, and biological evaluation of a novel series of 1-methyl-1H-imidazole, as potent Jak2 inhibitors to modulate the Jak/STAT pathway, are described. Using the C-ring fragment from our first clinical candidate AZD1480 (2 ...

    Structure based design, synthesis, and biological evaluation of a novel series of 1-methyl-1H-imidazole, as potent Jak2 inhibitors to modulate the Jak/STAT pathway, are described. Using the C-ring fragment from our first clinical candidate AZD1480 (24), optimization of the series led to the discovery of compound 19a, a potent, orally bioavailable Jak2 inhibitor. Compound 19a displayed a high level of cellular activity in hematopoietic cell lines harboring the V617F mutation and in murine BaF3 TEL-Jak2 cells. Compound 19a demonstrated significant tumor growth inhibition in a UKE-1 xenograft model within a well-tolerated dose range.


    Related Citations: 
    • Discovery of 5-Chloro-N2-[(1S)-1-(5-Fluoropyrimidin-2-Yl)Ethyl]-N4-(5-Methyl-1H-Pyrazol-3-Yl)Pyrimidine-2,4-Diamine (Azd1480) as a Novel Inhibitor of the Jak/Stat Pathway.
      Ioannidis, S.,Lamb, M.L.,Wang, T.,Almeida, L.,Block, M.H.,Davies, A.M.,Peng, B.,Su, M.,Zhang, H.,Hoffmann, E.,Rivard, C.,Green, I.,Howard, T.,Pollard, H.,Read, J.,Alimzhanov, M.,Bebernitz, G.,Bell, K.,Ye, M.,Huszar, D.,Zinda, M.
      (2011) J.Med.Chem. 54: 262


    Organizational Affiliation

    AstraZeneca, Oncology Innovative Medicines, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
TYROSINE-PROTEIN KINASE JAK2
A, B
298Homo sapiensMutation(s): 2 
Gene Names: JAK2
EC: 2.7.10.2
Find proteins for O60674 (Homo sapiens)
Go to Gene View: JAK2
Go to UniProtKB:  O60674
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
ACT
Query on ACT

Download SDF File 
Download CCD File 
A, B
ACETATE ION
C2 H3 O2
QTBSBXVTEAMEQO-UHFFFAOYSA-M
 Ligand Interaction
XWW
Query on XWW

Download SDF File 
Download CCD File 
A, B
N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-n4-(1-methylimidazol-4-yl)-6-morpholino-1,3,5-triazine-2,4-diamine
C17 H21 F N10 O
TYCLYNVNWNBCRU-NSHDSACASA-N
 Ligand Interaction
Modified Residues  1 Unique
IDChainsTypeFormula2D DiagramParent
PTR
Query on PTR
A, B
L-PEPTIDE LINKINGC9 H12 N O6 PTYR
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.75 Å
  • R-Value Free: 0.246 
  • R-Value Work: 0.196 
  • Space Group: C 1 2 1
Unit Cell:
Length (Å)Angle (°)
a = 44.507α = 90.00
b = 126.889β = 97.53
c = 135.875γ = 90.00
Software Package:
Software NamePurpose
AMoREphasing
REFMACrefinement
SCALEPACKdata scaling
MOSFLMdata reduction

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2014-01-08
    Type: Initial release
  • Version 1.1: 2014-01-22
    Type: Database references
  • Version 1.2: 2017-06-28
    Type: Data collection